Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by the board and officers of Embecta Corp.
The firm is soliciting shareholders who purchased shares before November 25, 2025, to contact them regarding potential legal remedies or to discuss their rights.
This release is an attorney advertisement and does not constitute an official disclosure from Embecta or a court certification of any class action.